The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 14, 2021
Filed:
Aug. 14, 2020
Applicant:
Janssen Biotech, Inc., Horsham, PA (US);
Inventors:
Marc Chevrier, Collegeville, PA (US);
Kamyar Farahi, Blue Bell, PA (US);
Newman Yeilding, Ardmore, PA (US);
Assignee:
JANSSEN BIOTECH, INC., Horsham, PA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 38/20 (2006.01); A01K 67/027 (2006.01); A61K 39/00 (2006.01); C07K 14/54 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 38/208 (2013.01); A01K 67/0271 (2013.01); A61K 38/20 (2013.01); A61K 39/00 (2013.01); A61K 39/3955 (2013.01); C07K 14/5434 (2013.01); C07K 16/244 (2013.01); A61K 35/12 (2013.01); A61K 2035/122 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 16/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01);
Abstract
A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.